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Detection of cell-free DNA fragmentation and copy
number alterations in cerebrospinal fluid from
glioma patients
Florent Mouliere1,2,3,*,† , Richard Mair1,2,4,†, Dineika Chandrananda1,2 , Francesco Marass1,2,5,6,
Christopher G Smith1,2, Jing Su1,2, James Morris1,2, Colin Watts7, Kevin M Brindle1,2,8,**,‡ &
Nitzan Rosenfeld1,2,***,‡
Abstract
Glioma is difficult to detect or characterize using current liquid
biopsy approaches. Detection of cell-free tumor DNA (cftDNA) in
cerebrospinal fluid (CSF) has been proposed as an alternative to
detection in plasma. We used shallow whole-genome sequencing
(sWGS, at a coverage of < 0.4×) of cell-free DNA from the CSF of 13
patients with primary glioma to determine somatic copy number
alterations and DNA fragmentation patterns. This allowed us to
determine the presence of cftDNA in CSF without any prior
knowledge of point mutations present in the tumor. We also
showed that the fragmentation pattern of cell-free DNA in CSF is
different from that in plasma. This low-cost screening method
provides information on the tumor genome and can be used to
target those patients with high levels of cftDNA for further larger-
scale sequencing, such as by whole-exome and whole-genome
sequencing.
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Introduction
The detection rate and concentration of cell-free tumor DNA
(cftDNA) in the plasma of patients with glioma are extremely low
(Bettegowda et al, 2014), making glioma refractory to current
plasma-based liquid biopsy approaches. Recent studies using DNA
sequencing of CSF samples showed that the fraction of mutant DNA
in CSF was higher than in the plasma of glioma patients. However,
these methods were based on identification of mutations in tumor
biopsies and targeted sequencing (Wang et al, 2015) or large-scale,
untargeted, and expensive analyses using whole-exome sequencing
(WES; De Mattos-Arruda et al, 2015; Pentsova et al, 2016). Despite
these advances, detection of cftDNA in CSF remains challenging as
it is affected by both tumor heterogeneity and the location of the
tumor (Wang et al, 2015). The lack of somatic alteration hotspots in
gliomas, other than IDH mutations (Brennan et al, 2013), further
limits the utility of targeted assays.
Recent studies have examined fragmentation patterns in total
cell-free DNA (cfDNA) and specifically the tumor fraction of
cfDNA (called cftDNA) in plasma and urine samples (Jiang & Lo,
2016). Distinct mechanisms of DNA release have been proposed,
identifiable through the patterns of cfDNA fragmentation that they
produce (Thierry et al, 2016; Wan et al, 2017). Apoptosis is asso-
ciated with a pattern of chromatin cleavage that generates DNA
fragments of around 167 bp (Lo et al, 2010) and multiples
thereof. While fragments of DNA in the plasma generally display
a mean fragment size of 167 bp, samples from individuals with a
high tumor burden show a trend toward shorter sizes (Mouliere
et al, 2011; Underhill et al, 2016). Non-tumor cfDNA is present
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mainly as fragments of around 167 bp, while cftDNA fragments
are around 145 bp (Jiang et al, 2015; Underhill et al, 2016;
preprint: Mouliere et al, 2017). Furthermore, an oscillatory pattern
has been observed in the distribution of fragment lengths below
150 bp with a periodicity of 10 bp, which likely corresponds to
the length of DNA sections wrapped around the nucleosome (Fan
et al, 2010; Lo et al, 2010). The size profile of tumor-derived
DNA in CSF has not previously been characterized.
Results and Discussion
We used double-stranded library preparation and paired-end shal-
low whole-genome sequencing (sWGS) at low depth of coverage
(< 0.4×) to infer somatic copy number alterations (SCNAs) and
DNA fragment size distributions in CSF samples from 13 glioma
patients (Fig 1A and Appendix Fig S1). SCNAs were observed in
5/13 (39%) patients (Fig 1A and B). Despite the small cohort size
and limited sensitivity of sWGS, which generally detects the pres-
ence of cftDNA only down to concentrations of ~5% of total
cfDNA (Heitzer et al, 2013; Adalsteinsson et al, 2017), our rate of
detection was similar to previous studies performed with more
expensive genome-wide sequencing methods (De Mattos-Arruda
et al, 2015; Pentsova et al, 2016). Targeted methods that track
tumor mutations previously identified in each patient by DNA
sequencing of tissue biopsies have a higher rate of cftDNA
detection (Wang et al, 2015), but the requirement for invasive
biopsies makes these methods impractical and expensive in a clini-
cal setting. The levels of cfDNA in the CSF were associated with
the presence of SCNAs, and the CSF samples with the highest
cfDNA concentrations were those from patients with tumor
SCNAs (Fig 1A), but not associated with tumor volume
(Appendix Table S1). For one patient, tumor tissue DNA was
available from multiple subregions within the tumor (Fig 1C and
A C
B
Figure 1. SCNAs can be detected in the CSF of glioma patients and provide additional information about tumor heterogeneity.
A Concentration of total cell-free DNA (cfDNA) in 13 CSF samples. Samples in which SCNAs were detected are shown in dark blue and tended to have higher levels of
total cfDNA.
B Relative copy number estimation in 20 genes of interest, and 18 large genomic regions, determined by sWGS of CSF from 13 glioma patients. Genes are ordered by
genomic position, and their chromosomal locations are indicated in parentheses. Amplifications are shown in dark blue, deletions are in orange, and copy number
neutral regions are in gray. The top green bar indicates the tumor largest length dimension (< 42 mm vs. > 42 mm), and the top violet bar indicates the glioma
subtype. SCNAs were more frequently detected in CSF from patients with large glioblastoma tumors.
C SCNAs determined by sWGS in four tumor subparts (T1  T4) and the CSF sample, collected from patient G1. Amplifications are shown in dark blue, deletions are in
orange, and copy number neutral regions are in dark gray. sWGS from plasma and urine samples collected at the same time as the CSF sample showed no SCNAs.
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Appendix Fig S2). Shared alterations between the different tumor
subparts were observed in the CSF sample, even if some private
alterations were not detected. The SCNAs detected by sWGS in 28
genes commonly altered in glioblastoma showed good concordance
between the CSF and tumor tissue DNA samples (Fig 2A). Interest-
ingly, three genomic alterations, notably a loss of chromosome 10
and gain of chromosome 7, were missed in one of the four tumor
biopsies (G1_T1) but were detected in CSF (Fig 2A). In addition,
we compared the SCNAs spanning EGFR and PTEN between tumor
samples and the corresponding CSF samples for the 12 other
patients (Fig 2B). Detection and confirmation of the SCNA in the
CSF sample was influenced by the size of the tumor, the level of
cfDNA, and the glioma grade.
Paired-end sWGS also allowed analysis of the size distribution
of cfDNA fragments in the CSF samples (Fig 3A and B). For
patient G1, we analyzed the fragmentation pattern of cfDNA in
matched CSF, plasma, and urine samples (Fig 3A). The fragmenta-
tion pattern in CSF differed from that observed in the plasma and
urine samples (Fig 3A). Eight CSF samples (62%) exhibited
enrichment of DNA fragments at ~145 bp, and a low or absent
peak at ~167 bp (Fig 3B and Appendix Fig S3). Analysis of the
fragment size distribution showed that > 50% of the fragments
were smaller than 150 bp in the CSF samples (compared to
< 20% for the plasma samples; Fig 3C). SCNAs were observed
primarily in patients with a DNA fragmentation pattern that had a
peak at ~145 bp (Fig 3D). A peak at ~133 bp was also noted in
one patient, which may represent a fragmentation pattern associ-
ated with a histone variant (Melters et al, 2015; Appendix Fig S2).
The patients with detected cftDNA showed a shift toward shorter
fragment sizes and also an apparent reduction in the amplitude of
the 10 bp periodic peaks observed below 145 bp (Fig 3D and E).
Patients with detected SCNAs also had a relative enrichment of
fragments in the size range 220–320 bp (Fig 3E). In addition to
the shift toward shorter cfDNA fragment sizes in CSF (Mouliere
et al, 2011, 2014; Jiang et al, 2015; Underhill et al, 2016), we also
observed a negative correlation between the amplitude of the 10
bp periodic peak patterns in fragment size distributions, calcu-
lated from the size profile of sWGS data, and the levels of SCNAs
in these CSF samples (Fig 3F), (Pearson, 0.85, P = 0.0002).
Thus, an overall decrease in the peak fragment size was associ-
ated with a reduction in the amplitude of the subnucleosomal
peaks. The origin of the 10 bp oscillatory pattern is believed to be
due to variable accessibility of the DNA due to its winding around
the histone cores (Jiang & Lo, 2016). Alternative nuclease activi-
ties in cancer or alternate mechanisms of DNA release may
produce an alteration in this fragmentation pattern. The use of
this subnucleosomal fragmentation signature enabled us to iden-
tify those CSF samples in which there were higher concentrations
of cftDNA, irrespective of the analysis of point mutations or
SCNAs.
In summary, untargeted sWGS (< 0.4× coverage) of CSF cfDNA
from 13 patients with primary brain tumors identified SCNAs in
5/13 patients. In one patient where multiple tumor samples were
analyzed, SCNAs detected in the CSF cfDNA recapitulated the over-
all alterations detected in tumor tissue DNA and further identified
SCNAs absent in one tumor region. Analysis of cfDNA size profiles
demonstrated relative enrichment in fragments of shorter length
(145 bp) in the CSF of patients with primary brain tumors. This
increase in the number of shorter DNA fragments correlated with
the presence of tumor-derived SCNAs in the CSF. Finally, we
observed a significant negative correlation between the amplitude of
the periodic 10 bp peaks in fragment size distribution and the levels
of SCNAs. This fragmentation signature provides an alternative way
to detect the presence of cftDNA in CSF that requires no prior
knowledge of point mutations or SCNAs within the tumor. The
combination of SCNAs and fragmentation analysis of cfDNA by
sWGS provides important genomic information at low cost and
more rapidly when compared with WES or targeted sequencing
guided by analysis of tumor biopsies (De Mattos-Arruda et al, 2015;
Wang et al, 2015; Pentsova et al, 2016; Adalsteinsson et al, 2017).
This approach could be used to identify samples for in-depth and
more costly analysis by genome-wide or capture sequencing
(Adalsteinsson et al, 2017).
A
B
Figure 2. Detection of SCNAs in CSF is influenced by tumor grade, cfDNA
concentration, and contact between the tumor and CSF.
A Heat map summarizing the SCNAs detected by sWGS of 28 genes of
interest in tumor biopsies and CSF from patient G1 (four tumor subparts
and one CSF sample). Amplifications are shown in dark blue, deletions are
in orange, and copy number neutral regions are in light gray.
B Heat map summarizing detection of EGFR and PTEN alterations in tumor
tissue and in CSF samples. Shared detection in tissue and CSF is indicated
in green, detection of the alteration only in tissue in orange, and non-
detection in blue. The top bars indicate the cfDNA concentration (copies/ml;
in a range of purples), the size of the tumors (in a range of browns), the
type of glioma (in a range of blues), and whether the tumor was in direct
contact with the CSF or not (based on MRI, green or red, respectively).
Samples are ranked from the left to right by decreasing concentration of
cfDNA (copies/ml).
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Materials and Methods
Sample collection and DNA extraction
Thirteen glioma patients were recruited from Addenbrooke’s Hospi-
tal, Cambridge, UK, as part of the BLING study (REC—15/EE/0094).
Written informed consent was obtained from the patients; the stud-
ies were conducted in accordance with the Declaration of Helsinki
and were approved by an Institutional Review Board. Lumbar punc-
ture was performed immediately prior to craniotomy for tumor
debulking. After sterile field preparation, the thecal sac was cannu-
lated between the L3 and L5 intervertebral spaces using a 0.61 mm
gauge lumbar puncture needle, and 10 ml of CSF was removed. All
samples were immediately placed on ice and then rapidly transferred
to a pre-chilled centrifuge for processing and storage at 80°C.
Samples were centrifuged at 1,500 g at 4°C for 10 min, then centri-
fuged at 20,000 g for a further 10 min, and aliquoted into 2-ml
microtubes for storage at 80°C (Sarstedt, Germany). DNA was
extracted from single aliquots (2 ml) of the pre-operative CSF
samples using the QIAamp circulating nucleic acid kit (Qiagen)
following the manufacturer’s instructions. The elution volume was
50 ll. Internal oligonucleotide controls, based on sequence frag-
ments from the Xenopus tropicalis genome, were used to estimate
the efficiency of DNA extraction.
Shallow whole-genome sequencing
Indexed sequencing libraries were prepared using a commercially
available kit (ThruPLEX Plasma-Seq, Rubicon Genomics). Libraries
were pooled in equimolar amounts and sequenced to < 0.4× depth of
coverage on a HiSeq 4000 (Illumina) generating 150-bp paired-end
reads. Sequence data were analyzed using an in-house pipeline where
paired-end sequence reads were aligned to the human reference
genome (GRCh37) using BWA-MEM following the removal of contam-
inating adapter sequences. PCR and optical duplicates were marked
using MarkDuplicates (Picard Tools) feature, and these were excluded
from downstream analysis along with reads of low mapping quality
and supplementary alignments. When necessary, reads were down-
sampled to 10 million in all samples for comparison purposes. The
amplitude of the 10 bp periodic peaks was calculated from the sWGS
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Figure 3. Distribution of DNA fragment sizes in the CSF is related to the presence of tumor DNA.
A Fragment size distribution, determined by sWGS, in CSF (blue line), plasma (red dashed line), and urine (black dashed line) from patient G1. The three samples were
collected simultaneously before initiation of treatment.
B Fragment size distribution of cfDNA, determined by sWGS, in CSF from 13 glioma patients. The samples contained a high fraction of reads from DNA fragments with
lengths corresponding to ~145 bp and ~167 bp. The fragment size profile of cfDNA from the plasma sample from patient G1 is shown in red. All samples were
collected simultaneously before initiation of treatment.
C Cumulative frequency analysis of the average density of fragment size in CSF (blue) and plasma (red). The vertical dashed line represents 167 bp.
D Mean fragment size density in patients with detected SCNAs in the CSF (yellow), and those with no detected SCNAs (dark blue).
E Log2 ratio of the difference in cfDNA fragment sizes between CSF samples with detected SCNAs and those samples in which no SCNAs were detected.
F The amplitude of the 10 bp periodic peaks in fragment size is a signature for non-tumor DNA in the CSF. The amplitude of the 10 bp periodic peaks in fragment
length distribution (in the range between 75 and 150 bp, see Materials and Methods) when compared to the mean copy number alteration calculated from sWGS
revealed a significant negative correlation (Pearson 0.85; P = 0.0002).
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data as follows: From the samples with clear peaks, the local maxima
and minima in the range 75–150 bp were calculated. The average of
their positions across the samples was calculated: (minima: 84, 96,
106, 116, 126, 137, 148; and maxima: 81, 92, 102, 112, 122, 134, 144).
To compute the “amplitude statistic”, we calculated the sum of the
height of the maxima and subtracted the sum of the minima. The
larger this difference, the more distinct are the peaks. The height of
the x bp peak is defined as the number of fragments with
length × divided by the total number of fragments. To define local
maxima, we selected the positions y such that y was the largest value
in the interval [y  2, y + 2]. The same rationale was used to pick
minima. The somatic copy number aberration analysis was performed
in R using a software suite for shallow whole-genome sequencing
copy number analysis named CNAclinic (https://github.com/sdchand
ra/CNAclinic) as well as the QDNAseq pipeline. Sequencing reads
were randomly sampled to 10 million reads per dataset and allocated
into equally sized (30 Kbp) non-overlapping bins throughout the
length of the genome. Read counts in each bin were corrected to
account for sequence GC content and mappability, and bins overlap-
ping “blacklisted” regions (derived from the ENCODE project + 1000
Genomes database) prone to artifacts were excluded from down-
stream analysis (Benjamini & Speed, 2012; Chandrananda et al,
2014). Read counts in test samples were median-normalized and log2-
transformed to obtained copy number ratio values per genomic bin.
Next, bins were segmented using both circular binary segmentation
and hidden Markov model-based algorithms, and an averaged log2R
value per bin was calculated (Olshen et al, 2004; Ha et al, 2012).
Data availability
Sequencing data for this study are deposited in the EGA database,
accession number EGAS00001003255 (https://www.ebi.ac.uk/ega/
studies/EGAS00001003255). Other data associated with this study
are present in the paper or Appendix.
Expanded View for this article is available online.
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